These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 32034718)

  • 1. Histone Modifying Enzymes and Chromatin Modifiers in Glioma Pathobiology and Therapy Responses.
    Ciechomska IA; Jayaprakash C; Maleszewska M; Kaminska B
    Adv Exp Med Biol; 2020; 1202():259-279. PubMed ID: 32034718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deregulation of histone-modifying enzymes and chromatin structure modifiers contributes to glioma development.
    Maleszewska M; Kaminska B
    Future Oncol; 2015 Sep; 11(18):2587-601. PubMed ID: 26289459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deregulated chromatin remodeling in the pathobiology of brain tumors.
    Spyropoulou A; Piperi C; Adamopoulos C; Papavassiliou AG
    Neuromolecular Med; 2013 Mar; 15(1):1-24. PubMed ID: 23114751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in chromatin machinery and pediatric high-grade glioma.
    Lulla RR; Saratsis AM; Hashizume R
    Sci Adv; 2016 Mar; 2(3):e1501354. PubMed ID: 27034984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of selected inhibitors of histone modifying enzyme on C6 glioma cells.
    Maleszewska M; Steranka A; Kaminska B
    Pharmacol Rep; 2014 Feb; 66(1):107-13. PubMed ID: 24905315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modifying Chromatin by Histone Tail Clipping.
    Azad GK; Swagatika S; Kumawat M; Kumawat R; Tomar RS
    J Mol Biol; 2018 Sep; 430(18 Pt B):3051-3067. PubMed ID: 30009770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis and treatment of lymphomas in the era of epigenetics.
    Chebly A; Chouery E; Ropio J; Kourie HR; Beylot-Barry M; Merlio JP; Tomb R; Chevret E
    Blood Rev; 2021 Jul; 48():100782. PubMed ID: 33229141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR promoter exhibits dynamic histone modifications and binding of ASH2L and P300 in human germinal matrix and gliomas.
    Erfani P; Tome-Garcia J; Canoll P; Doetsch F; Tsankova NM
    Epigenetics; 2015; 10(6):496-507. PubMed ID: 25996283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Global DNA Methylation Patterns in Human Gliomas and Their Interplay with Other Epigenetic Modifications.
    J Dabrowski M; Wojtas B
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31311166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Domain cross-talk in regulation of histone modifications: Molecular mechanisms and targeting opportunities.
    Longbotham JE; Zhang MY; Fujimori DG
    Curr Opin Chem Biol; 2020 Aug; 57():105-113. PubMed ID: 32758979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chromatin modifications remodel cardiac gene expression.
    Mathiyalagan P; Keating ST; Du XJ; El-Osta A
    Cardiovasc Res; 2014 Jul; 103(1):7-16. PubMed ID: 24812277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping chromatin accessibility and active regulatory elements reveals pathological mechanisms in human gliomas.
    Stępniak K; Machnicka MA; Mieczkowski J; Macioszek A; Wojtaś B; Gielniewski B; Poleszak K; Perycz M; Król SK; Guzik R; Dąbrowski MJ; Dramiński M; Jardanowska M; Grabowicz I; Dziedzic A; Kranas H; Sienkiewicz K; Diamanti K; Kotulska K; Grajkowska W; Roszkowski M; Czernicki T; Marchel A; Komorowski J; Kaminska B; Wilczyński B
    Nat Commun; 2021 Jun; 12(1):3621. PubMed ID: 34131149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA methylation and chromatin modifiers in colorectal cancer.
    Vymetalkova V; Vodicka P; Vodenkova S; Alonso S; Schneider-Stock R
    Mol Aspects Med; 2019 Oct; 69():73-92. PubMed ID: 31028771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of epigenetic modifications, long-range contacts, enhancers and topologically associating domains in the regulation of glioma grade-specific genes.
    Grabowicz IE; Wilczyński B; Kamińska B; Roura AJ; Wojtaś B; Dąbrowski MJ
    Sci Rep; 2021 Aug; 11(1):15668. PubMed ID: 34341417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of epigenetic reprogramming on antitumor immune responses in glioma.
    McClellan BL; Haase S; Nunez FJ; Alghamri MS; Dabaja AA; Lowenstein PR; Castro MG
    J Clin Invest; 2023 Jan; 133(2):. PubMed ID: 36647827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone modification: cause or cog?
    Henikoff S; Shilatifard A
    Trends Genet; 2011 Oct; 27(10):389-96. PubMed ID: 21764166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism.
    Morel D; Almouzni G; Soria JC; Postel-Vinay S
    Ann Oncol; 2017 Feb; 28(2):254-269. PubMed ID: 28426098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small molecule modulators of histone acetylation and methylation: a disease perspective.
    Selvi BR; Mohankrishna DV; Ostwal YB; Kundu TK
    Biochim Biophys Acta; 2010; 1799(10-12):810-28. PubMed ID: 20888936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic deregulation in cancer: Enzyme players and non-coding RNAs.
    Farooqi AA; Fayyaz S; Poltronieri P; Calin G; Mallardo M
    Semin Cancer Biol; 2022 Aug; 83():197-207. PubMed ID: 32738290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.